Article references (11 references )


  1. Champion RH, Burton JL, Burns DA et al. Textbook of Dermatology. Boston, Mass: Blackwell. 1998: 2186-91.

  2. Wollina U. Pyoderma gangrenosum: a review. Orphanet J Rare Dis. 2007; 2: 19. PubMed | Google Scholar

  3. Arfa S, Youssef M, Bennaser M, Ines L, Kechida M, Mohamed M et al. Profil clinique et étiologique du pyoderma gangrenosum. La revue de Médecine Interne. June 2016; 37 (Supplément 1): A157-A158. Google Scholar

  4. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006; 333(7560): 181-4. PubMed | Google Scholar

  5. Bister V, Mäkitalo L, Jeskanene L, Saarialho-Kere U. Expression of MMP-9, MMP-10 and TNF-α and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum. J CutanPathol. 2007; 34(12): 889-98. PubMed | Google Scholar

  6. Riyaz N, Mary V, Sasidharanpillai S, Roshin RA, Snigdha O, Latheef EN et al. Pyoderma gangrenosum: a clinico-epidemiologicalstudy. Indian J Dermatol Venereol Leprol. 2017 Jan-Feb; 83(1): 33-39. PubMed | Google Scholar

  7. Kolios AGA, Gübeli A, Meier B, Maul JT, Kündig T, Nilsson J et al. Clinical disease patterns in a regional Swiss cohort of 34 pyoderma gangrenosum patients. Dermatology. 2017; 233(4): 268-276. Epub2017 Nov 7. PubMed | Google Scholar

  8. Blitz NM, Rudikoff D. Pyoderma Gangrenosum. Mt Sinai J Med. 2001; 68(4-5): 287-97. PubMed | Google Scholar

  9. Soutou B, Vignon-Pennamen D, Chosidow O. Neutrophilic dermatoses. Rev Med Interne. 2011 May; 32(5): 306-13. Epub 2010 Oct 8. PubMed

  10. Su WP, Schroeter AL, Perry HO, Powell FC. Powell Histopathologic and immunopathologicstudy of pyoderma gangrenosum. J CutanPathol. 1986 Oct; 13(5): 323-30. PubMed

  11. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind, placebo controlled trial. Gut. 2006 Apr; 55(4): 505-9. Epub 2005 Sep 27. PubMed | Google Scholar